Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Sandro Pignata, Michael Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Cagatay Taskiran, Charles Anderson, Sakari Hietanen, Tashanna Myers, Radoslaw Madry, Lyndsay Willmott, Alain Lortholary, Jessica Thomes-Pepin, Carol Aghajanian, Carolyn McCourt, Ashley Stuckey, Xiaohua Wu, Shin Nishio, Larry J. Copeland, Yvette He, Luciana Molinero, Sheetal Patel, Yvonne G. Lin, Victor K. Khor, Kathleen N. Moore

Open source

DOI: 10.1016/j.ygyno.2023.06.018
Published: 2023-10
Container: Gynecologic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2023.06.018,
  title = {Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer},
  author = {Sandro Pignata and Michael Bookman and Jalid Sehouli and Austin Miller and Richard T. Penson and Cagatay Taskiran and Charles Anderson and Sakari Hietanen and Tashanna Myers and Radoslaw Madry and Lyndsay Willmott and Alain Lortholary and Jessica Thomes-Pepin and Carol Aghajanian and Carolyn McCourt and Ashley Stuckey and Xiaohua Wu and Shin Nishio and Larry J. Copeland and Yvette He and Luciana Molinero and Sheetal Patel and Yvonne G. Lin and Victor K. Khor and Kathleen N. Moore},
  year = {2023},
  journal = {Gynecologic Oncology},
  doi = {10.1016/j.ygyno.2023.06.018},
  url = {https://doi.org/10.1016/j.ygyno.2023.06.018}
}

RIS

TY  - JOUR
TI  - Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
AU  - Sandro Pignata
AU  - Michael Bookman
AU  - Jalid Sehouli
AU  - Austin Miller
AU  - Richard T. Penson
AU  - Cagatay Taskiran
AU  - Charles Anderson
AU  - Sakari Hietanen
AU  - Tashanna Myers
AU  - Radoslaw Madry
AU  - Lyndsay Willmott
AU  - Alain Lortholary
AU  - Jessica Thomes-Pepin
AU  - Carol Aghajanian
AU  - Carolyn McCourt
AU  - Ashley Stuckey
AU  - Xiaohua Wu
AU  - Shin Nishio
AU  - Larry J. Copeland
AU  - Yvette He
AU  - Luciana Molinero
AU  - Sheetal Patel
AU  - Yvonne G. Lin
AU  - Victor K. Khor
AU  - Kathleen N. Moore
PY  - 2023
JO  - Gynecologic Oncology
DO  - 10.1016/j.ygyno.2023.06.018
UR  - https://doi.org/10.1016/j.ygyno.2023.06.018
ER  -

APA

Pignata, S., Bookman, M., Sehouli, J., Miller, A., Penson, R. T., Taskiran, C., Anderson, C., Hietanen, S., Myers, T., Madry, R., Willmott, L., Lortholary, A., Thomes-Pepin, J., Aghajanian, C., McCourt, C., Stuckey, A., Wu, X., Nishio, S., Copeland, L. J., He, Y., Molinero, L., Patel, S., Lin, Y. G., Khor, V. K., & Moore, K. N. (2023). Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2023.06.018

Source records

crossref · retrieved 2026-09-25T23:08:42.256Z